{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+A-Part+2&page=2",
    "query": {
      "intervention": "Treatment A-Part 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+A-Part+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T14:32:05.711Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06567015",
      "title": "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "STX-241",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2024-09-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06567015"
    },
    {
      "nct_id": "NCT04742634",
      "title": "Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "DEC-C",
          "type": "DRUG"
        },
        {
          "name": "MyeloSeq-HD",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 209,
      "start_date": "2022-05-12",
      "completion_date": "2033-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04742634"
    },
    {
      "nct_id": "NCT03355209",
      "title": "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lennox Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 0.2 or 0.8 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 296,
      "start_date": "2017-11-27",
      "completion_date": "2024-05-23",
      "has_results": true,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03355209"
    },
    {
      "nct_id": "NCT03081858",
      "title": "Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer Cell Transitional",
        "Non-Muscle Invasive Bladder Cancer",
        "Bladder Cancer",
        "Urinary Bladder",
        "Transitional Cell Carcinoma of the Bladder",
        "Urinary Bladder Neoplasms",
        "Urologic Neoplasms",
        "Urogenital Neoplasms",
        "Urinary Bladder Diseases",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "TSD-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lipac Oncology LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-05-17",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hanover",
          "state": "Maryland"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03081858"
    },
    {
      "nct_id": "NCT00631748",
      "title": "Quetiapine for the Reduction of Cocaine Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cocaine Dependence",
        "Cocaine Abuse",
        "Cocaine Addiction",
        "Drug Abuse",
        "Substance Abuse"
      ],
      "interventions": [
        {
          "name": "quetiapine fumarate",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cognitive-behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-02",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2014-03-31",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00631748"
    },
    {
      "nct_id": "NCT01298934",
      "title": "LBH589 (Panobinostat) for the Treatment of Myelofibrosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Post-Essential Thrombocythemia Related Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "LBH589",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ronald Hoffman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2009-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01298934"
    },
    {
      "nct_id": "NCT04208178",
      "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced HER2+Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 19,
      "start_date": "2020-07-16",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 2,
      "location_summary": "Fayetteville, Arkansas • Los Angeles, California",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04208178"
    },
    {
      "nct_id": "NCT03336268",
      "title": "Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance Use Disorders",
        "Overdose"
      ],
      "interventions": [
        {
          "name": "POINT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2018-02-12",
      "completion_date": "2021-12-09",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Muncie, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03336268"
    },
    {
      "nct_id": "NCT06667908",
      "title": "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "JNJ-90301900",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Concurrent Chemo/Radiation Therapy (cCRT)",
          "type": "RADIATION"
        },
        {
          "name": "Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2024-12-06",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 18,
      "location_summary": "La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06667908"
    },
    {
      "nct_id": "NCT00377390",
      "title": "ICATA Asthma Mechanistic Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "6 Years to 20 Years"
      },
      "enrollment_count": 224,
      "start_date": "2006-10",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-09-27T14:32:05.711Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • New York, New York • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377390"
    }
  ]
}